Results 21 to 30 of about 177,431 (250)

Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.

PLoS ONE, 2013
HIV-1 infected cells are eliminated in infected individuals by a variety of cellular mechanisms, the best characterized of which are cytotoxic T cell and NK cell-mediated killing.
Adjoa Smalls-Mantey, Mark Connors, Quentin J Sattentau   +2 more
doaj   +1 more source

Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity

Journal of Hematology & Oncology, 2021
Resistance to anti-cancer monoclonal antibody (mAb) therapy remains a clinical challenge. Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell viability and NK cell-mediated antibody ...
Zhaoming Wang, Chaobo Yin, Lawrence G. Lum, Andrean Simons, George J. Weiner   +4 more
doaj   +1 more source

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis

Cell Reports, 2018
Summary: Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc-receptor-expressing immune cells, including neutrophils. However, the
Hanke L. Matlung, Liane Babes, Xi Wen Zhao, Michel van Houdt, Louise W. Treffers, Dieke J. van Rees, Katka Franke, Karin Schornagel, Paul Verkuijlen, Hans Janssen, Pasi Halonen, Cor Lieftink, Roderick L. Beijersbergen, Jeanette H.W. Leusen, Jaap J. Boelens, Ingrid Kuhnle, Jutte van der Werff Ten Bosch, Karl Seeger, Sergio Rutella, Daria Pagliara, Takashi Matozaki, Eiji Suzuki, Catharina Willemien Menke-van der Houven van Oordt, Robin van Bruggen, Dirk Roos, Rene A.W. van Lier, Taco W. Kuijpers, Paul Kubes, Timo K. van den Berg   +28 more
doaj   +1 more source

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Haematologica, 2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated ...
Inger S. Nijhof, Jeroen J. Lammerts van Bueren, Berris van Kessel, Pascale Andre, Yannis Morel, Henk M. Lokhorst, Niels W.C.J. van de Donk, Paul W.H.I. Parren, Tuna Mutis   +8 more
doaj   +1 more source

Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents

Frontiers in Immunology, 2021
The transferrin receptor 1 (TfR1), also known as cluster of differentiation 71 (CD71), is a type II transmembrane glycoprotein that binds transferrin (Tf) and performs a critical role in cellular iron uptake through the interaction with iron-bound Tf ...
Pierre V. Candelaria, Lai Sum Leoh, Manuel L. Penichet, Manuel L. Penichet, Manuel L. Penichet, Manuel L. Penichet, Manuel L. Penichet, Tracy R. Daniels-Wells   +7 more
doaj   +1 more source

Applicability of Traditional In Vitro Toxicity Tests for Assessing Adverse Effects of Monoclonal Antibodies: A Case Study of Rituximab and Trastuzumab

Antibodies, 2018
Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing ...
Arathi Kizhedath, Simon Wilkinson, Jarka Glassey   +2 more
doaj   +1 more source

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody

Frontiers in Immunology, 2022
Targeting CD19 represents a promising strategy for the therapy of B-cell malignancies. Although non-engineered CD19 antibodies are poorly effective in mediating complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC)
Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, Dorothee Winterberg, Steffen Krohn, Thomas Theocharis, Elisa Cappuzzello, Anja Lux, Falk Nimmerjahn, Ralf J. Ludwig, Marta Lustig, Thies Rösner, Thomas Valerius, Denis Martin Schewe, Christian Kellner, Katja Klausz, Matthias Peipp   +16 more
doaj   +1 more source

Generation of CD16A gene knockout human embryonic stem cell line using CRISPR/Cas9

Stem Cell Research, 2022
CD16A is a receptor for the Fc portion of immunoglobulin G, and is involved in the antibody dependent cellular cytotoxicity (ADCC) of nature killer cells(Zhu et al., 2020) and antibody dependent enhancement (ADE) of virus infections(Wan et al., 2020 ...
Shunjie Wu, Haimei Deng, Bo Lu, Lihua Yuan, Xiaobo Wang   +4 more
doaj   +1 more source

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Cells, 2020
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a ...
Ilaria Saltarella, Vanessa Desantis, Assunta Melaccio, Antonio Giovanni Solimando, Aurelia Lamanuzzi, Roberto Ria, Clelia Tiziana Storlazzi, Maria Addolorata Mariggiò, Angelo Vacca, Maria Antonia Frassanito   +9 more
doaj   +1 more source